South Texas Pediatric Minority Based CCOP

南德克萨斯州儿科少数族裔社区临床肿瘤学项目（STP-MB-CCOP）首次成立于1990年，是 目前在其第17个年头的资金，是两个唯一的儿科CCOP在美国之一。的主要研究者 STP-MB-CCOP传统上是德克萨斯大学儿科血液学/肿瘤学部门的医生 圣安东尼奥健康科学中心（UTHSCSA）。STP-MB-CCOP作为4个儿科机构的联合体运作：1） CHRISTUS圣罗莎儿童医院（CSRCH）（圣安东尼奥，得克萨斯州）; 2）Drivel儿童医院（Corpus Christi，得克萨斯州）; 3） 卫理公会儿童医院（圣安东尼奥，德克萨斯州），以及4）威尔福德霍尔医疗中心的美国陆军儿科肿瘤学项目 (San Antonio，TX）。 STP-MB-CCOP将继续向青年提供最高标准的护理（即获得临床试验） 得克萨斯州南部受癌症影响的人口。此外，它将继续扩大其在人口方面的翅膀， 研究涉及南德克萨斯州人口的健康和社会经济问题。 它将针对癌症护理提供的孤儿（即患有癌症的青少年和年轻人），以了解和消除干扰他们获得临床试验和生存的障碍。 它将集中精力为居住在下格兰德河山谷的儿科癌症患者提供临床试验。 它将通过解决以下问题进一步评估肥胖对ALL患者生存的影响：1）肥胖的遗传学; 2） 肥胖对ALL发生的可能影响; 3）肥胖对肝功能和化疗代谢的影响 用于治疗ALL的药物;和4）肥胖对ALL幸存者中糖尿病和心血管疾病的后期发展的影响。 它将作为遗传研究的临床基地，描述边境人口中儿科癌症人群的特征，包括 基因混合和多态性研究影响癌症风险和结果。 它将用于开发更多的试点研究，以解决青年的独特性（生物或社会经济） 得克萨斯州南部受癌症影响的人口。

The South Texas Pediatric Minority-Based Community Clinical Oncology Program (STP-MB-CCOP) was first formed in 1990, is currently in its 17th year of funding and is one of two solely pediatric CCOPs in the United States. The Principal Investigator of the STP-MB-CCOP has traditionally been a physician in the Division of Pediatric Hematology/Oncology of the University of Texas Health Science Center at San Antonio (UTHSCSA). The STP-MB-CCOP operates as a consortium of 4 pediatric institutions: 1) CHRISTUS Santa Rosa Children's Hospital (CSRCH) (San Antonio, TX); 2) Driscoll Children's Hospital (Corpus Christi, TX); 3) Methodist Children's Hospital (San Antonio, TX), and 4) the U.S. Army pediatric oncology program at Wilford Hall Medical Center (San Antonio, TX). The STP-MB-CCOP will continue to provide access to the highest standard of care (i.e. access to clinical trials) to the youth population of South Texas affected by cancer. In addition, it will continue to expand its wings in regards to population-based studies dealing with health and socio-economic issues specific to the population of South Texas. ¿ It will target the orphans of cancer care delivery (i.e. adolescents and young adults with cancer) in order to understand and abolish the barriers interfering with their access to clinical trials and survival. ¿ It will concentrate on bringing access to clinical trials to pediatric cancer patients residing in the Lower Rio Grande Valley. ¿ It will further assess the impact of obesity on the survival of ALL patients by addressing issues such as: 1) genetics of obesity; 2) possible impact of obesity on the development of ALL; 3) impact of obesity on liver function and metabolism of chemotherapy agents used to treat ALL; and 4) impact of obesity on later development of diabetes and cardiovascular disease in ALL survivors. ¿ It will serve as a clinical base for genetic studies characterizing the pediatric cancer population in border population including genetic admixture and polymorphism studies in genes influencing both cancer risks and outcomes. ¿ It will be used to develop additional pilot studies that will address the uniqueness (biologic or socio-economic) of the youth population of South Texas affected by cancer.